MacuLogix Inc.
Early diagnosis and tracking of age-related macular degeneration
This article was originally published in Start Up
Executive Summary
The AdaptDx from MacuLogix Inc. has the potential to be the first practical diagnostic instrument for early detection of AMD. Akin to routine peripheral vision testing for glaucoma, the noninvasive desktop device measures impaired dark adaptation (the speed with which vision is recovered when moving from a brightly lit environment to darkness), an early-stage marker of AMD development.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.